What is B. Riley’s Estimate for WVE Q1 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE) – Research analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of Wave Life Sciences in a research report issued to clients and investors on Wednesday, November 13th. B. Riley analyst M. El-Saadi expects that the company will post earnings of ($0.25) per share for the quarter. B. Riley has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.09) per share. B. Riley also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.24) EPS.

WVE has been the subject of a number of other research reports. JPMorgan Chase & Co. lifted their target price on shares of Wave Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, October 17th. Truist Financial increased their price objective on shares of Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. Raymond James raised shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $13.00 to $22.00 in a research note on Wednesday, October 16th. Wells Fargo & Company boosted their price target on Wave Life Sciences from $11.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, October 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Wave Life Sciences in a research report on Wednesday. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.89.

Wave Life Sciences Price Performance

WVE stock opened at $13.67 on Friday. The business has a fifty day moving average price of $10.76 and a 200 day moving average price of $7.54. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -12.32 and a beta of -1.20. Wave Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $16.74.

Insider Activity

In other news, insider Chris Francis sold 208,836 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $13.67, for a total transaction of $2,854,788.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Kyle Moran sold 17,146 shares of the business’s stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total transaction of $154,314.00. Following the sale, the chief financial officer now owns 19,777 shares of the company’s stock, valued at $177,993. This trade represents a 46.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 452,056 shares of company stock valued at $5,955,438. Company insiders own 29.10% of the company’s stock.

Institutional Investors Weigh In On Wave Life Sciences

Several institutional investors have recently bought and sold shares of the stock. Maverick Capital Ltd. raised its stake in shares of Wave Life Sciences by 31.0% during the 3rd quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company’s stock worth $82,390,000 after purchasing an additional 2,378,159 shares during the period. Artal Group S.A. increased its holdings in Wave Life Sciences by 34.7% in the 1st quarter. Artal Group S.A. now owns 4,051,400 shares of the company’s stock worth $24,997,000 after acquiring an additional 1,044,000 shares during the last quarter. Emerald Advisers LLC lifted its holdings in Wave Life Sciences by 15.6% during the third quarter. Emerald Advisers LLC now owns 2,881,510 shares of the company’s stock valued at $23,628,000 after purchasing an additional 388,280 shares during the last quarter. State Street Corp boosted its position in Wave Life Sciences by 2.6% during the third quarter. State Street Corp now owns 2,321,248 shares of the company’s stock worth $19,034,000 after purchasing an additional 57,822 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Wave Life Sciences by 14.3% in the third quarter. Geode Capital Management LLC now owns 2,269,664 shares of the company’s stock valued at $18,615,000 after purchasing an additional 283,419 shares during the period. Institutional investors own 89.73% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.